Cite
Additional file 1: of CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
MLA
Fennell, Dean, et al. Additional File 1: Of CONFIRM: A Double-Blind, Placebo-Controlled Phase III Clinical Trial Investigating the Effect of Nivolumab in Patients with Relapsed Mesothelioma: Study Protocol for a Randomised Controlled Trial. Jan. 2018. EBSCOhost, https://doi.org/10.6084/m9.figshare.6158138.v1.
APA
Fennell, D., Kirkpatrick, E., Cozens, K., Nye, M., Lester, J., Hanna, G., Steele, N., Szlosarek, P., Danson, S., Joanne Lord, Ottensmeier, C., Barnes, D., Hill, S., Mihalis Kalevras, Maishman, T., & Griffiths, G. (2018). Additional file 1: of CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. https://doi.org/10.6084/m9.figshare.6158138.v1
Chicago
Fennell, Dean, Emma Kirkpatrick, Kelly Cozens, Mavis Nye, Jason Lester, Gerard Hanna, Nicola Steele, et al. 2018. “Additional File 1: Of CONFIRM: A Double-Blind, Placebo-Controlled Phase III Clinical Trial Investigating the Effect of Nivolumab in Patients with Relapsed Mesothelioma: Study Protocol for a Randomised Controlled Trial,” January. doi:10.6084/m9.figshare.6158138.v1.